Primary Recipient

BETASTEM THERAPEUTICS INC

Amount

$326,697.00

Award Date

9/30/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

The long term goal is to develop an efficient, safe clinical treatment for diabetic retinopathy using stem cells from the patient's bone marrow or blood that have been activated to repair damaged vessels in the eye. Diabetic retinopathy remains theleading

Recipients Connected to Award

Recipient	Role	Amount
BETASTEM THERAPEUTICS INC	Primary recipient	$177,238.00
UNIVERSITY OF FLORIDA	Sub-recipient	$149,459.00